Biohaven .(US:BHVN) Prnewswireยท2025-08-15 13:28Core Viewpoint - The complaint against Biohaven alleges violations of federal securities laws due to misleading statements regarding the regulatory prospects of its drug troriluzole for spinocerebellar ataxia (SCA) and the efficacy of BHV-7000 for bipolar disorder, which could significantly impact the company's financial condition [2] Group 1 - Biohaven's stock price fell by $3.84 per share, or 19.53%, closing at $15.82 per share following the announcement of an extended PDUFA date for the troriluzole NDA [3] - The FDA extended the PDUFA date for the troriluzole NDA by three months to allow for a full review of Biohaven's recent submissions [3] - An advisory committee meeting is planned by the FDA to discuss the application, although no date has been set [3] Group 2 - The lead plaintiff in the class action is the investor with the largest financial interest in the relief sought and is responsible for directing the litigation on behalf of the class [4] - Any member of the putative class can move to serve as lead plaintiff or remain an absent class member without affecting their ability to share in any recovery [4] Group 3 - Faruqi & Faruqi, LLP is encouraging individuals with information regarding Biohaven's conduct to come forward, including whistleblowers and former employees [5]